A detailed history of Tower Research Capital LLC (Trc) transactions in I Mab stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,015 shares of IMAB stock, worth $3,613. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,015
Holding current value
$3,613
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.03 - $1.72 $4,135 - $6,905
4,015 New
4,015 $4,000
Q4 2023

Feb 13, 2024

SELL
$1.21 - $1.9 $4,247 - $6,669
-3,510 Reduced 12.48%
24,608 $46,000
Q3 2023

Nov 14, 2023

BUY
$1.18 - $3.06 $24,158 - $62,647
20,473 Added 267.8%
28,118 $37,000
Q2 2023

Aug 14, 2023

BUY
$2.95 - $3.85 $8,723 - $11,384
2,957 Added 63.08%
7,645 $22,000
Q1 2023

May 09, 2023

SELL
$3.08 - $7.39 $5,639 - $13,531
-1,831 Reduced 28.09%
4,688 $16,000
Q4 2022

Feb 10, 2023

SELL
$3.22 - $4.86 $201,733 - $304,479
-62,650 Reduced 90.58%
6,519 $27,000
Q3 2022

Nov 10, 2022

BUY
$4.01 - $12.34 $270,225 - $831,567
67,388 Added 3783.72%
69,169 $278,000
Q2 2022

Aug 15, 2022

SELL
$8.27 - $18.43 $28,175 - $62,791
-3,407 Reduced 65.67%
1,781 $20,000
Q1 2022

May 12, 2022

BUY
$12.54 - $46.93 $53,006 - $198,373
4,227 Added 439.85%
5,188 $84,000
Q4 2021

Feb 14, 2022

SELL
$45.28 - $74.5 $64,116 - $105,492
-1,416 Reduced 59.57%
961 $46,000
Q3 2021

Nov 15, 2021

BUY
$57.18 - $84.43 $88,686 - $130,950
1,551 Added 187.77%
2,377 $172,000
Q2 2021

Aug 16, 2021

BUY
$47.86 - $83.95 $6,030 - $10,577
126 Added 18.0%
826 $69,000
Q1 2021

May 17, 2021

BUY
$44.38 - $63.97 $21,524 - $31,025
485 Added 225.58%
700 $34,000
Q4 2020

Feb 16, 2021

BUY
$32.94 - $47.15 $7,082 - $10,137
215 New
215 $10,000

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $74.8M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.